Introduction
GAS is a major human pathogen. GAS infections are associated with considerable global morbidity and mortality. In particular, invasive Group A Streptococcus (iGAS) disease (when GAS is isolated from a normally sterile body site) has been associated with case fatality rates of around 15% in developed countries and higher still in developing countries. 1 Those at highest risk of iGAS disease include the very young and elderly, Indigenous populations, and patients with medical co-morbidities such as diabetes, immunosuppression, obesity and malignancy. 1, 2 Further, the incidence of iGAS disease varies geographically, with reported annual rates of between 2 and 4 cases per 100,000 population per year in developed countries, including Canada, the United Kingdom (UK) and the United States (USA). [3] [4] [5] Data from several regions suggest that the incidence of iGAS disease has increased since the 1980s, following a decline over the previous century. [6] [7] [8] [9] [10] [11] [12] [13] A recent study from the UK demonstrated that household contacts of an iGAS case (defined as someone who had direct person-to-person contact with the case in their household during the 7 days before the case's onset of illness ) have a considerably increased risk of subsequently developing iGAS themselves (secondary iGAS disease).
14 These authors observed an approximately 2,000-times increased risk of iGAS disease in the close contacts of index cases (RR: 1,940, 95% CI; 1,240-2,880) compared with the background risk. Assuming that index cases were notified quickly and effective chemoprophylaxis could be provided, it was estimated that the number of close contacts needed to treat (NNT) in order to prevent one secondary iGAS case was 407 (95% confidence interval, CI: 273-807). The NNT was much lower for motherneonate pairs and cohabitating couples aged 75+ years old, however, at 50 (95% CI: 27-393) and 82 (95% CI: 46-417) respectively. 14 iGAS disease is notifiable to public health authorities in several developed countries, including Canada, Sweden, UK, and the USA. 10, [15] [16] [17] In Australia, iGAS disease is not nationally notifiable, although it is notifiable in Queensland and the Northern Territory. There are no national Australian guidelines regarding the prevention of secondary iGAS disease, and jurisdictional variation in chemoprophylaxis recommendations exists (Table 1) .
The most recent epidemiological study of iGAS disease used 2002-2004 data to estimate a mean annual incidence of 2.7 (95% CI: 2.3-3.2) cases per 100,000 population per year in Victoria. This study identified a 2,011-times (95% CI: 413-5,929-times) increased risk of secondary infection for close contacts of cases, very similar to that identified by the UK study. 14, 27 An analysis of Victorian Hospital Pathogen Surveillance Scheme (VHPSS) data from 2005-2009 identified a mean annual total of 86 iGAS isolates, and the 5 most common emm-types (emm-1, -73, -41, -69, -89) comprised 54.7% of the total sample. 28 Of recent concern is an increase in paediatric iGAS disease in Victoria, with more children hospitalised during the winter of 2017 alone than were reported for either of the preceding 2 years. 29 To date however, there are no contemporary systematic data on temporal trends of iGAS disease in Victoria, and knowledge of the circulating GAS strains associated with iGAS disease is limited. Furthermore, the burden of secondary infection is unknown. Accordingly, using data from a longstanding laboratory-based surveillance system, we sought to assess the trends and molecular epidemiology of iGAS disease in Victoria, over an 11 year period, from 2007 to 2017.
Methods
Minimum risk ethics approval was obtained from the University of Melbourne Biomedical Sciences Human Ethics Advisory Group (ID: 1853000.1).
Setting, data sources and case definition
The VHPSS is a voluntary, laboratorybased surveillance system established at the No (Unless ≥2 related cases occur) Close contacts should receive information about GAS (e.g. Maternal sepsis fact sheet (http://www.health.nsw.gov.au/ Infectious/factsheets/Pages/maternalsepsis.aspx)) and have a heightened awareness of the signs and symptoms of GAS for 30 days after the diagnosis of invasive GAS in the index patient. They should be advised to seek medical advice if they develop symptoms. Chemoprophylaxis of index cases' household contacts may be considered if there is:
• A household with 2 or more diagnoses of iGAS linked temporally, • Close contacts with increased susceptibility to severe infection, such as injecting drug users.
• Close contacts with symptoms suggestive of localized GAS infection such as sore throat, fever, skin infection. All close contacts of patients with iGAS infection should be advised that they are at increased risk of iGAS infection in the next 30 days, and should be aware of the symptoms and of the importance of seeking medical attention promptly should these occur. Chemoprophylaxis is recommended for iGAS cases' household (and homeless) contacts when:
• Mother-neonatal pair is affected (or neonatal twins)
• iGAS index case has severe disease • Last contact with case was during the period 7 days before onset of symptoms up until 24 hours after the case's commencement of effective antibiotic treatment. Provide iGAS fact sheet to household contacts to inform them of iGAS disease symptoms to watch for and seek treatment if signs/symptoms of iGAS disease appear.
If household contact has symptoms of GAS infection, or is mother-neonate pair, provide chemoprophylaxis (and hospitalisation, if symptoms of severe disease occur).
If there are two or more cases of iGAS within a 30 day time period from index case presentation, then the entire household should be issued chemoprophylaxis and the iGAS fact sheet. Chemoprophylaxis should be offered to household contacts of severe iGAS disease cases if they have been exposed to the case during the period of 7 days before onset of symptoms up until 24 hours after the case's commencement of antimicrobial therapy.
Alert household contacts to signs/symptoms of iGAS disease (severe or otherwise), advise them to seek medical attention immediately should they develop clinical manifestations of GAS within 30 days of index case's diagnosis. 
Microbiological analysis and molecular typing
Identification of GAS isolates was carried out at individual laboratories prior to specimens being sent to MDU PHL. Polymerase chain reaction (PCR) analysis and DNA sequencing of the emm gene was performed using previously described methods.
32 Emm-types were assigned using the Blast-emm database at https://www2a.cdc.gov/ ncidod/biotech/strepblast.asp
Statistical Analysis
Basic descriptive analyses were performed. When investigating whether there was a significant difference in reported proportions, the test of equal or given proportions was used. When calculating population-based iGAS and iMD incidence rates with 95% CI, population estimates based on census data (available from the Australian Bureau of Statistics website) 33 were used as denominator data. The Chi-squared test was used when investigating whether reported rates were significantly different. Differences in proportions and rates were considered statistically significant if p<0.05. Poisson regression models were used to investigate whether differences in the iGAS incidence varied according to age group, gender and year. Incidence rate ratios (IRR) were generated from univariate models, including univariate models stratified by age, and adjusted IRRs (aIRR) were generated from a multivariable model that included age group, gender and year (Stata v.14.
34
).
Results

Descriptive epidemiology of cases and trends in iGAS incidence
Between 1 January 2007 and 31 December 2017, a total of 1,311 iGAS cases were identified through the VHPSS. The majority of patients (1,309/1,311; 99.8%) had bloodstream isolates and the remainder were from cerebrospinal fluid. Over one-quarter (27.9%) of cases were aged 70+ years old, with 20.4% of cases aged <20 years; 52.9% of cases were male. A statistically significant variation in the seasonal distribution of cases was not observed (p=0.0572, Chisquared test).
The number of iGAS cases increased from 83 in 2007, to 220 in 2017 (Figure 1 ), an increase of 165%.
The peak annual incidence rate was 3.63 cases (95% CI: 3.17-4.13) per 100,000 population per year in 2017, a 67% increase from the previous year (p<0.05). The mean annual incidence was 2.11 cases (95% CI: 1.78-2.50) per 100,000 population per year. The incidence was 48% higher in the latter part of the study period had the highest iGAS incidence (4.7 per 100,000 population per year) followed by those aged <5 years (3.9 per 100,000 population per year). Overall, males had higher iGAS incidence than females (IRR: 1.14, 95% CI: 1.03-1.28), however this association was not consistent across agegroups. When stratified by age, among those aged 20-49 years, males had lower incidence than females (IRR: 0.57, 95% CI: 0.43-0.74). Conversely, among those aged 60+ years, males had higher incidence than females (IRR 1.54, 95% CI: 1.31-1.82; Figure 2 , Table 2 ).
Comparison with invasive meningococcal disease cases
In comparison to iGAS cases, the number of iMD cases reported to VHPSS (with blood and cerebrospinal fluid isolates only) increased from 38 cases in 2007 to 67 in 2017, a 76% increase, with the annual incidence rate peaking at 1.10 (95% CI: 0.86-1.39) per 100,000 population per year (Figure 1 ). The mean annual incidence rate for the whole study period was 0.60 cases (95% CI: 0.45-0.82) per 100,000 population per year. The annual number of iMD cases notified to the NNDSS for Victoria was also considerably lower than the number of iGAS cases reported to VHPSS throughout the study period, peaking at 89 cases in 2017 (p<0.05).
Emm-type distribution by year
The majority of iGAS cases had emm-typing information available (N=1,202, 91.7%). A diverse array of 140 different emm-types was identified. The most common was emm-1 (n=274 isolates, 22.8%), followed by emm-89 (N=115, 9.6%, Figure 3) . 
DISCUSSION
Based on data from the VHPSS, the iGAS incidence in Victoria increased over the period 2010-2017, peaking at 3.6 (95% CI: 3.2-4.2) per 100,000 population per year in 2017. This observation is consistent with increases in iGAS incidence across a range of countries with similar Human Development Indices to Australia, such as New Zealand, the US, UK, and Canada. 4, 9, [11] [12] [13] 35 The recent increase in iGAS disease is concerning, especially as our estimates likely undercount the true burden of disease by 20-40%, given the voluntary, passively collected surveillance data available from the VHPSS. 28 Why older males had the highest IRR of iGAS is unclear, but similar case distributions have been noted in a number of other studies. 27, 36, 37 Despite limitations in the surveillance data, in particular undercounting of iGAS cases, the annual incidence of iGAS exceeded the incidence of notified iMD over the entire study period. While case numbers for both conditions peaked in 2017, the number of iGAS cases was 2.5-times higher than iMD cases that year. This finding is consistent with Steer et al.'s 2012 observation that the rate of iGAS disease in industrialised countries is 2-4 times higher than the rate of meningococcal disease. 38 While both conditions share high case fatality rates and potential to cause lifelong disability 39, 40 , only iMD is presently notifiable in Victoria. 41 Although efforts to develop a multivalent GAS vaccine targeting the M-protein (encoded by the emm gene) are in progress. 42, 43 , this study observed a diverse range of iGAS emm-types, with none in particular appearing to have driven the recent upsurge in cases. To illustrate, the 10 most prevalence emm-types comprised <60% of the total sample and 68% in 2017. These findings indicate the emergence of greater diversity in emm-types compared to the previous iGAS 28 The emm-1 strain remained the most commonly identified in both studies. 28 Considerable diversity in GAS emm-types has also been reported for Africa and the Pacific region as a whole. 44 An iGAS study in Sydney in 2008 and 2010 identified somewhat greater diversity than our study, but was limited to 2 years of data collection. The authors identified 72 cases with 27 different emm-types 11 , while we identified 174 cases and 46 strains for the same years ( Figure 4) . Our results highlight the role of chemoprophylaxis in disease control, as an iGAS vaccine would need to have extremely broad coverage in order to effectively prevent all cases. The J8-DT vaccine may provide a promising means of generating broad protection against a diverse range of GAS strains. 45 This vaccine is still in development, but streptococcal infection following its administration in mice has been demonstrated to boost vaccine-induced immunity. 46 The recent data from the UK highlighted the potential benefits and challenges of chemoprophylaxis in preventing secondary iGAS cases. 14 The evidence of increased risk of secondary disease among close contacts, in conjunction with rising incidence rates of iGAS, demonstrate the urgent public health need to make iGAS notifiable, both in Victoria and nationally. Potential benefits of making iGAS notifiable would include improved epidemiological surveillance; enhanced followup of cases -including contact tracing and chemoprophylaxis provision; and a requirement for laboratories to send isolates for additional characterisation. Ideally, this would encompass whole genome sequencing of isolates, which, in addition to in silico emm typing, would enable assessment of relatedness between isolates. This would provide a deeper understanding of possible outbreaks and/or transmission networks, as has been previously described overseas. 14 In summary, high-quality surveillance information is needed to better inform effective control and prevention measures for this condition. Introducing a mandatory requirement for case notification, in conjunction with enhanced laboratory characterisation of isolates could facilitate such improvements.
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